drugset / Trial / NCT05629364
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
RandomizedSingle-groupQuadruple-blindTreatment
Summary
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, versus Vehicle Control in the treatment of Dry Eye Disease in Patients with Autoimmune Disease
Timeline
- Start
- 2023-03-15
- Primary completion
- 2024-01-09
- Completion
- 2024-01-09
Outcome
Outcome not reported
Stopped: “Study halted prematurely but potentially will resume”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KIO-101 | Unknown | 0.15 % | Topical |
| Subject | KIO-101 | Unknown | 0.3 % | Topical |